Bull case
Waters is supported by a durable replacement cycle in analytical instruments, with Alliance iS pricing 15%–20% above prior models and roughly 20% of LC replacements shifting to the new platform, while aging flow cytometers and mass spectrometry systems should keep upgrades flowing over several years. The early 2026 merger with BD’s life science and diagnostics business roughly doubled the company and adds a new earnings-growth driver, with about $200 million of cost savings by 2027 and potential operating-margin expansion of 170–200 bps as integration, mix, and revenue synergies build. Fundamental demand is also reinforced by Waters’ embedded role in regulated pharma QA/QC, ~15% exposure to drug manufacturing, and recurring reagent, service, and software revenue, while 2026 organic constant-currency growth of 7%–9% signals healthy underlying momentum.